A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced… (NCT05255133) | Clinical Trial Compass
CompletedNot Applicable
A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment
Belgium22 participantsStarted 2017-10-09
Plain-language summary
Prospective, multicentric, single arm, POC study to evaluate the value of CtDNA in follow-up of patients treated with everolimus, with or without somatostatin analogues for advanced gastroenteropancreatic or lung neuroendocrine tumours.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Haemoglobin ≥ 9.0 g/dL
✓. ANC ≥ 1,500/mm3 (≥1.5 x 109/L)
✓. Platelets ≥ 100,000/mm3 (≥ 100x 109/L)
✓. INR ≤ 2.0
✓. Alanine aminotransferase and aspartate aminotransferase ≤2.5xULN (Upper limit of normal) (or ≤ 5 if hepatic metastases are present)
✓. Total serum bilirubin ≤ 1.5 x ULN (≤ 3 ULN for patients known to have Gilbert Syndrome)
✓. Fasting serum cholesterol ≤ 300 mg/dL or 7.75 mmol/L
. Uncontrolled diabetes defined as fasting glycemia \> 150 mg/dl.
✕. Acute and chronic, active infectious disorders and non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this study therapy.